A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers

Trial Profile

A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs PCO 371 (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 19 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Jun 2015 New trial record
    • 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top